Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

To get local purchase information on this product, click here

Product Description

Purified recombinant human PTPN13 (Asp2169-Lys2485) Phosphatase, supplied as a GST fusion protein.


Non-receptor protein tyrosine phosphatase 13 (PTPN13) is also known as Fas-associated phosphatase-1 (FAP-1) because it associates with the regulatory domain of the Fas receptor and negatively regulates Fas signaling (1). PTPN13 protein contains: an N-terminal kinase non-catalytic C-lobe domain (KIND); followed by a Four-point-one/Ezrin/Radixin/Moesin (FERM) domain; five PDZ domains; and a C-terminal phosphatase domain (2,3). The function of the KIND domain is not clear, while the FERM domain is thought to bind cell surface receptors and help target PTPN13 to the plasma membrane. The PDZ domains may help PTPN13 bind selectively to target proteins and maintain substrate specificity (2). Dephosphorylation of Fas receptor by PTPN13 reduces the presence of the receptor at the cell surface and inhibits Fas-mediated apoptosis (4). Both Fas receptor and its inhibitor are regulated through NF-κB signaling. Activated Fas receptor induces NF-κB signaling, which promotes expression of the Fas inhibitor PTPN13 (5). Induced overexpression of PTPN13 in vitro blocks IRS-1/PI3K/Akt signaling by dephosphorylating IRS-1, leading to reduced cell survival and induction of apoptosis (6). Mutations in the corresponding PTPN13 gene and abnormal phosphatase activity are associated with colorectal cancer, suggesting that PTPN13 plays an important role in regulating cancer cell proliferation (7). Similar studies indicate that PTPN13 may act as a tumor suppressor in hepatocellular carcinoma as inhibition of PTPN13 phosphatase activity results in increased cancer cell proliferation (8).


1.  Sato, T. et al. (1995) Science 268, 411-5.

2.  Erdmann, K.S. (2003) Eur J Biochem 270, 4789-98.

3.  Saras, J. et al. (1994) J Biol Chem 269, 24082-9.

4.  Ivanov, V.N. et al. (2003) Mol Cell Biol 23, 3623-35.

5.  Ivanov, V.N. et al. (2006) J Biol Chem 281, 1840-52.

6.  Dromard, M. et al. (2007) Cancer Res 67, 6806-13.

7.  Wang, Z. et al. (2004) Science 304, 1164-6.

8.  Yeh, S.H. et al. (2006) Clin Cancer Res 12, 1097-108.


Entrez-Gene Id 5783
Swiss-Prot Acc. Q12923


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
DELFIA® is a registered trademark of PerkinElmer, Inc.